Allied Market Research
Loading...
0

Influenza Vaccine Market Expected to Reach $10,127.0 Million by 2030

 

Report Code : A01118

quote increase in government support and surveillance regarding vaccination against influenza on the national and global levels to monitor the supply, distribution, and administration of flu vaccines drive the growth of the influenza vaccine market. quote

Onkar Sumant
Manager, Healthcare at Allied Market Research

Get 20% Free Customization In This Report
Follow us on Social Media:       
 

According to a new report published by Allied Market Research, titled, “Global Influenza Vaccine Market by Vaccine Type, Type, Technology, Age Group, and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2021–2030" the global influenza vaccine market was valued at $5024.60 million in 2020, and is projected to reach $10,127.0 million by 2030, registering a CAGR of 7.20% from 2021 to 2030.

Influenza is an acute respiratory infection caused by influenza viruses leading to illness that affects humans and animals. These viruses are genetically dynamic and evolve unpredictively each year on seasonal basis. Thus, seasonal influenza epidemics are caused by newer strains that are antigenically different from the previous circulating strains. The changes in the genetics of the influenza virus strains further results in the development of new vaccines yearly.

Factors that boost the growth of the influenza vaccine market include increase in government support and surveillance regarding vaccination against influenza on the national and global levels to monitor the supply, distribution, and administration of flu vaccines. Moreover, rise in investment by leading market players across the globe and surge in government funding which has facilitated the launch of therapeutically effective vaccines drive the market growth.

Key factors that challenge the growth of influenza vaccine market include process that generally takes about 10-15 years to develop and establish its safety and efficacy of influenza vaccine in the market. Regulatory requirements for clinical trials vary in countries, which may delay development of vaccines. This in turn limits the growth of the market.

The COVID-19 outbreak is anticipated to have a positive impact on growth of the global influenza vaccine market. The COVID-19 pandemic has stressed the healthcare systems in the world. The number of populations effected with COVID-19 virus increases, surge the demand for influenza vaccine. The influenza vaccine will not prevent COVID-19, but will decrease the illness, death and hospitalization. According to European Congress of Clinical Microbiology & infectious diseases (ECCMID), in 2021, it was reported that around 75,000 COVID-19 patients having shot of influenza vaccine are less prone to sepsis, stroke and deep vein thrombosis. As per the same source, in 2021, it was observed that flu vaccine may offer protection against COVID-19 virus. The patient suffering from COVID-19, and vaccinated with influenza vaccine are also less likely to admitted in intensive care unit. Subsequently, this leads to increase in demand for influenza vaccine.

The influenza vaccine market is segmented into vaccine type, technology, age group, route of administration and region. By vaccine type, it is divided into quadrivalent and trivalent. The quadrivalent type segment was the major revenue contributor in 2020, owing to its ability to immunize four influenza virus strains (two A subtypes and two B subtypes — H1N1 and H3N2 and Victoria and Yamagata, respectively). By technology, it is classified into egg-based and cell-based. The egg-based technology dominates the technology segment as it is most commonly used in production of both inactivated and live-attenuated vaccines. By age group, it is bifurcated into pediatric and adult. The adult age group segment was the highest contributor in the market in 2020 and is expected to remain dominant during the forecast period, owing to higher risks of developing serious complications from influenza due to weaker immune response. By route of administration, it is categorized into injection and nasal spray. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

North America was the highest revenue contributor in the global influenza vaccine market and accounted for a 47.80% share in 2020. On the other hand, Middle East and Africa is expected to grow at a CAGR of 8.0%, owing to rise in incidences of influenza among children and increase in disposable income.

Some of the key players operating in the influenza vaccine market are AstraZeneca plc., Biodiem, CSL Limited, Emergent BioSolutions, F. Hoffmann-La Roche Ltd., Gamma Vaccines Pty Ltd., GlaxoSmithKline plc, Merck & Co. Inc. (Merck Sharp & Dohme Corp.), Novartis AG, Pfizer, Inc., Sanofi Pasteur SA, and Sinovac Biotech Ltd.

Key Findings Of The Study

  • By vaccine type, quadrivalent segment accounted for nearly 63% share of the Influenza Vaccine market in 2020.
  • By technology, the egg based segment expected to grow at a CAGR of 7.70% from 2021 to 2030.
  • By age group, the Adult segment held largest market share in of 61% in 2020 and is expected to remain dominant throughout the forecast period.
  • By route of administration, the injection segment expected to grow at a CAGR of 7.40% from 2021 to 2030.
  • By region, North America is expected to provide lucrative market growth opportunities and grow at a CAGR of 6.9% from 2021 to 2030.

Need More Information

pr-det-talk Talk to David (Europe)

pr-det-talk Talk to Sona Padman (Americas)

5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States

pr-det-phone Toll Free: +1-800-792-5285

pr-det-phone UK: +44-845-528-1300

pr-det-phone Hong Kong: +852-301-84916

pr-det-phone India (Pune): +91 2066346060

pr-det-phone Fax: +1(855) 550-5975

pr-det-phone help@alliedmarketresearch.com

 

For Media Inquiries, Please Contact

Tushar Nagose
Communications Officer
Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at
media@alliedmarketresearch.com

 
 

First time buyer?
Check offers and discount on this report
To get this report

 
Click Here
 
 

quote Influenza Vaccine Market by Vaccine Type (Quadrivalent and Trivalent), Technology (Egg-based, and Cell culture), Age Group (Pediatric, and Adult), and Route of Administration (Injection, and Nasal Spray): Global Opportunity Analysis and Industry Forecast, 2021–2030 quote

View Report
 
 
Avenue Video Loading...

Avenue: Entire Library membership of Allied Market Research Reports at your disposal

  • Avenue is an innovative subscription-based online report database.
  • Avail an online access to the entire library of syndicated reports on more than 3,514 niche industries and company profiles on more than 12,953 firms across 11 domains.
  • A cost-effective model tailored for entrepreneurs, investors, and students & researchers at universities.
  • Request customizations, suggest new reports, and avail analyst support as per your requirements.
  • Get an access to the library of reports at any time from any device and anywhere.

 
 

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time of readers

 

Featured Readings

 
rep-img

Published Date Jan 2021

Surgical Equipment Market

Download Sample
rep-img

Published Date Nov 2020

Medical Implant Market

Download Sample
 

Get Fresh content delivered

Get insights on topics that matter to your business. Stay updated on the area that interests you.

 
Get Industry Data Alerts
 

Buy Full Version
"Influenza Vaccine Market"
Purchase Enquiry